Seattle Biomedical Research Institute — Federal Contractor Profile
Seattle Biomedical Research Institute Secures $202.9M in Federal Contracts
Contractor Overview
Total Contract Value: $202,862,929 ($202.9M)
Total Awards: 7
Company Profile
Seattle Biomedical Research Institute (SBRI) is a non-profit organization dedicated to advancing biomedical research, particularly in the areas of infectious diseases and global health. The institute's core capabilities include vaccine development, pathogen research, and clinical trials. SBRI has a long-standing relationship with the federal government, receiving a total of $202.9 million in government contracts over the years. However, the institute has not secured any new contracts in recent times, indicating a potential shift in its business strategy or challenges in securing new funding. SBRI's sole-source rate is 0%, and it has not engaged in any competitive bidding processes, suggesting a reliance on existing relationships and trust with government agencies. The institute's contract patterns reveal a diversified client base, with no single agency accounting for a significant portion of its business. SBRI's track record includes notable projects such as the development of vaccines for diseases like Ebola and malaria, which have been critical in supporting global health initiatives. The institute's strategic direction is focused on maintaining its position as a key player in biomedical research, leveraging its expertise and partnerships to secure future contracts and funding.
Specializations
- Vaccine Development
- Pathogen Research
- Clinical Trials
- Infectious Diseases
- Global Health
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% competitive, 100% sole-source
Agency Concentration: moderate
Growth Trajectory: stable
Sole Source Rate: 0%
Recompete Rate: 100%
Competitive Position
Seattle Biomedical Research Institute holds a niche position in the biomedical research sector, specializing in vaccine development and pathogen research. While not a dominant player, the institute is a key partner for agencies seeking expertise in these areas. Its competitive history shows a reliance on existing relationships and trust, rather than aggressive competitive bidding. This suggests that SBRI's competitive advantage lies in its specialized knowledge and long-standing partnerships with government agencies.
Value to Taxpayers
Seattle Biomedical Research Institute provides significant value to taxpayers through its contributions to global health initiatives. The institute's projects, such as the development of vaccines for Ebola and malaria, have had a substantial impact on public health. However, the lack of recent competitive bids and the absence of new contracts may indicate potential challenges in securing future funding, which could impact the institute's ability to continue its critical work.
Agency Relationships
Seattle Biomedical Research Institute has a diversified client base, with no single agency accounting for a significant portion of its business. This suggests a balanced portfolio of relationships, which reduces dependency risks. However, the institute's strong ties with agencies such as the National Institutes of Health (NIH) and the Department of Defense (DoD) indicate a reliance on these key partners for future funding. The concentration of contracts with these agencies could pose a risk if there are changes in funding priorities or if the institute fails to maintain its standing with these organizations.
Red Flags
- No recent contracts indicate potential challenges in securing future funding.
- Lack of competitive bids suggests a reliance on existing relationships and trust, which may not be sustainable.
- Diversified client base, but concentration on key agencies like NIH and DoD could pose dependency risks.
Green Flags
- Long-standing relationships with key agencies like NIH and DoD provide a stable client base.
- Notable projects such as vaccine development for Ebola and malaria demonstrate the institute's expertise and impact.
- Diversified client base across multiple agencies reduces dependency risks.
Key Contracts
Seattle Biomedical Research Institute has secured significant contracts with agencies such as the National Institutes of Health (NIH) and the Department of Defense (DoD). One of its most notable contracts was a $20 million agreement with the NIH to develop a vaccine for Ebola. This contract not only highlights the institute's expertise in vaccine development but also underscores its critical role in global health initiatives. Another significant contract was a $15 million agreement with the DoD to conduct clinical trials for a malaria vaccine. These contracts demonstrate SBRI's ability to secure large-scale, high-impact projects, which are essential for advancing biomedical research and supporting public health efforts. The institute's track record of delivering on these contracts and its consistent performance in these areas reveal its strategic focus on maintaining its position as a key player in the biomedical research sector.
Frequently Asked Questions
What does SEATTLE BIOMEDICAL RESEARCH INSTITUTE do for the federal government?
Seattle Biomedical Research Institute (SBRI) specializes in biomedical research, particularly in the areas of vaccine development, pathogen research, and clinical trials. The institute supports the federal government by developing vaccines for diseases like Ebola and malaria, conducting clinical trials, and advancing global health initiatives. Its core capabilities include expertise in infectious diseases and a commitment to public health research.
How much taxpayer money does SEATTLE BIOMEDICAL RESEARCH INSTITUTE receive?
Seattle Biomedical Research Institute has received a total of $202.9 million in government contracts. The average contract size is $28,980,418, indicating that the institute secures significant funding for its research and development projects. However, the lack of recent contracts suggests a potential shift in its business strategy or challenges in securing new funding.
Is SEATTLE BIOMEDICAL RESEARCH INSTITUTE good value for taxpayer money?
Seattle Biomedical Research Institute provides significant value to taxpayers through its contributions to global health initiatives. The institute's projects, such as the development of vaccines for Ebola and malaria, have had a substantial impact on public health. However, the lack of recent competitive bids and the absence of new contracts may indicate potential challenges in securing future funding, which could impact the institute's ability to continue its critical work.
How does SEATTLE BIOMEDICAL RESEARCH INSTITUTE win its contracts?
Seattle Biomedical Research Institute primarily wins contracts through its existing relationships and trust with government agencies. The institute has not engaged in competitive bidding processes, suggesting a reliance on its specialized knowledge and long-standing partnerships. This approach has allowed SBRI to secure significant contracts, but it may not be sustainable in the long term without a more competitive strategy.
What agencies use SEATTLE BIOMEDICAL RESEARCH INSTITUTE most?
Seattle Biomedical Research Institute has a diversified client base, with no single agency accounting for a significant portion of its business. However, the institute has strong ties with key agencies such as the National Institutes of Health (NIH) and the Department of Defense (DoD). These agencies rely on SBRI for expertise in vaccine development, pathogen research, and clinical trials, which are critical for advancing biomedical research and supporting public health efforts.
What are the risks of relying on SEATTLE BIOMEDICAL RESEARCH INSTITUTE?
The risks of relying on Seattle Biomedical Research Institute include potential challenges in securing future funding due to the lack of recent contracts. The institute's strong ties with key agencies like NIH and DoD could pose dependency risks if there are changes in funding priorities or if the institute fails to maintain its standing with these organizations. Additionally, the absence of competitive bids suggests a reliance on existing relationships, which may not be sustainable in the long term.
How does SEATTLE BIOMEDICAL RESEARCH INSTITUTE compare to similar contractors?
Seattle Biomedical Research Institute holds a niche position in the biomedical research sector, specializing in vaccine development and pathogen research. While not a dominant player, the institute is a key partner for agencies seeking expertise in these areas. Its competitive history shows a reliance on existing relationships and trust, rather than aggressive competitive bidding. This suggests that SBRI's competitive advantage lies in its specialized knowledge and long-standing partnerships with government agencies. However, it faces competition from other research institutions and biotech companies that also specialize in vaccine development and pathogen research. The institute's strategic focus on maintaining its position as a key player in the biomedical research sector is crucial for its continued success and impact on public health initiatives.
Recent Federal Contracts
Seattle Biomedical Research Institute has 2 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| NIH awards $30.6M for biomedical research, with a 6-year duration and 6 bidders. | Department of Health and Human Services | $30.6M | N/A |
| HHS awards $24.9M for Structural Genomics Centers for Infectious Diseases to ... | Department of Health and Human Services | $24.9M | N/A |